Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 50 of 95 results for template

  1. How we support healthtech commissioning

    practical support tools including real-life case studies and resource impact templates. Further resources and funding We understand that...

  2. Resource planner

    Our resource planner tool to help you plan for and implement NICE guidance.

  3. Technology appraisal and highly specialised technologies appeals

    Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.

  4. Assessing the resource impact of NICE guidance

    We estimate the costs or savings (resource impact) associated with technologies and guidelines so you can plan for and implement guidance.

  5. About interventional procedures guidance

    We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.

  6. Technology appraisal submission templates and supporting documents

    All the templates and supporting documents you need to make a technology appraisals submission with NICE.

  7. NICE HealthTech programme manual (PMG48)

    This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme

  8. NICE technology appraisal and highly specialised technologies guidance: the manual (PMG36)

    This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website

  9. About highly specialised technologies guidance

    Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England.

  10. NICE quality standards: process guide (PMG43)

    This guide describes the process NICE uses to develop NICE quality standards

  11. Privacy notice

    How we collect and use your personal information, and your rights under data protection legislation.

  12. Interventional procedures programme manual (PMG28)

    This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual

  13. Appeal panel membership

    The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.

  14. Developing NICE guidelines: the manual (PMG20)

    This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE

  15. Past appeals and decisions

    Past technology appraisal appeals and decisions

  16. Patient access schemes and pricing agreements

    appropriate proposal template, either for a complex scheme or a simple discount scheme: proposal template: complex scheme...

  17. Compliance with nice-approved medicines or treatments

    Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.

  18. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  19. Technology appraisal data: appraisal recommendations

    Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  20. Planning your technology appraisal submission to NICE

    Engage at the optimal time for your technology appraisal, to achieve NICE guidance at the same time as marketing authorisation.

  21. UK licensing and technology appraisals

    NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.

  22. Charging timeline

    A timeline showing where in the NICE evaluation process companies will be charged.

  23. Accessibility

    NICE wants as many people as possible to be able to use our services, and we have designed it to be accessible.

  24. Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)

    This guide outlines the appeal process for the technology appraisal and highly specialised technologies guidance. It sets out the process that NICE follows for appeals and provides guidance for those who wish to make an appeal or who are considering doing so

  25. About technology appraisal guidance

    Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.

  26. Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)

    Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.

  27. Measuring the use of NICE guidance

    NICE works with partners including Public Health England, NHS England and NHS Improvement to assess services and support innovation and best practice.

  28. Overweight and obesity management (QS212)

    This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.

  29. Taking a proportionate approach to technology appraisals

    Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.

  30. Charging procedure

    Charging procedure for NICE technology appraisal and highly specialised technologies evaluations

  31. Fees for technology appraisals and highly specialised technologies

    NICE fees for technology appraisals and highly specialised technologies

  32. What is technology appraisal guidance?

    NICE's technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.

  33. Technology appraisal methods and processes used before 2022

    Before 2022, we used different processes for assessing technologies. You can view the previous process and methods guides below.

  34. How we develop technology appraisal guidance

    A step-by-step summary about how we develop our technology appraisal guidance.

  35. Contributing to the development of our guidelines

    We've created the guides and resources on this page to help people who are involved in developing NICE guidelines.

  36. Contributing to the development of our guidelines

    We've created the guides and resources on this page to help people who are involved in developing NICE guidelines.

  37. General practice - keep your practice up-to-date

    Information and links to key resources that will help you keep your practice up-to-date.

  38. Data collection agreement

    technology appraisal submission to NICE Technology appraisal submission templates and supporting documents Technology appraisal data:...

  39. Cost saving guidance

    panel Save money with NICE guidance Our resource impact reports and templates allow you to estimate savings for your local setting more...

  40. NICE-wide topic prioritisation: the manual (PMG46)

    This manual sets out the process for how new guidance topics and updates to existing NICE guidance are identified, prioritised and routed at NICE, and the decision-making framework used by the NICE prioritisation board

  41. Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template (PMG24)

    This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies evaluations process. It explains what information NICE requires and the format in which it should be presented

  42. Modular updates for our technology appraisal guidance

    technology appraisal submission to NICE Technology appraisal submission templates and supporting documents Technology appraisal data:...

  43. Tuberculosis (NG33)

    This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.

  44. Learning disabilities: health checks, action plans and ethnicity (IND266)

    This indicator covers the percentage of patients on the learning disability register, who: received a learning disability health check and had a completed health action plan in the preceding 12 months and, have a recording of ethnicity. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM250

  45. Learning disabilities: health checks and action plans (IND265)

    This indicator covers the percentage of patients on the learning disability register who received a learning disability health check and had a completed health action plan in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM249

  46. NICE decision aid: process guide (PMG42)

    This process guide provides an overview of the key principles used for developing NICE decision aids. It ensures that robust, quality-assured decision aids for people using and providing health and social care services are developed in an open, transparent and timely way, with appropriate input from key groups

  47. Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education (NG213)

    This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.

  48. SecurAcath for securing percutaneous catheters (HTG440)

    Evidence-based recommendations on SecurAcath for securing percutaneous catheters.

  49. Stockholm3 for prostate cancer screening (MIB303)

    NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .

  50. Fever in under 5s (QS64)

    This quality standard covers the assessment and early management of fever with no obvious cause in babies and children (from birth to 5 years). It describes high-quality care in priority areas for improvement.